CO6640319A2 - Formulación en polvo seca que comprende una droga antimuscarínica - Google Patents
Formulación en polvo seca que comprende una droga antimuscarínicaInfo
- Publication number
- CO6640319A2 CO6640319A2 CO12230869A CO12230869A CO6640319A2 CO 6640319 A2 CO6640319 A2 CO 6640319A2 CO 12230869 A CO12230869 A CO 12230869A CO 12230869 A CO12230869 A CO 12230869A CO 6640319 A2 CO6640319 A2 CO 6640319A2
- Authority
- CO
- Colombia
- Prior art keywords
- dry powder
- powder formulation
- formulation
- relates
- antimuscarinic drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con una formulación en polvo seca adecuada para una administración por inhalación por medio de un inhalador de polvo seco, que comprende un derivado aminoéster de la fórmula (I), que actúa como un antagonista del receptor muscarínico. La invención también se relaciona con el proceso de preparación de la formulación, con su uso en la prevención y/o el tratamiento de un amplio rango de condiciones incluyendo trastornos respiratorios, tales como enfermedad pulmonar obstructiva crónica (EPOC) y asma, con envases que comprenden una formulación inhalable en polvo seca y un inhalador de polvo seco. Las composiciones de la invención son formulaciones farmacéuticas en la forma de un polvo seco inhalable, que comprende, como ingrediente activo, partículas micronizadas de un compuesto de la fórmula general (I).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10166903 | 2010-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6640319A2 true CO6640319A2 (es) | 2013-03-22 |
Family
ID=42942112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12230869A CO6640319A2 (es) | 2010-06-22 | 2012-12-20 | Formulación en polvo seca que comprende una droga antimuscarínica |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110308519A1 (es) |
| EP (1) | EP2585047A1 (es) |
| JP (1) | JP2013529606A (es) |
| KR (1) | KR20130111967A (es) |
| CN (1) | CN102946868B (es) |
| AR (1) | AR081967A1 (es) |
| AU (1) | AU2011269238A1 (es) |
| BR (1) | BR112012032330A2 (es) |
| CA (1) | CA2803418A1 (es) |
| CL (1) | CL2012003450A1 (es) |
| CO (1) | CO6640319A2 (es) |
| EA (1) | EA201291306A1 (es) |
| MA (1) | MA34326B1 (es) |
| MX (1) | MX2012014541A (es) |
| NZ (1) | NZ604983A (es) |
| PE (1) | PE20130282A1 (es) |
| SG (1) | SG186427A1 (es) |
| TN (1) | TN2012000566A1 (es) |
| TW (1) | TW201204412A (es) |
| UA (1) | UA107499C2 (es) |
| WO (1) | WO2011160920A1 (es) |
| ZA (1) | ZA201209682B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| RU2580835C2 (ru) * | 2010-06-22 | 2016-04-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Алкалоидные производные на основе сложных аминоэфиров и композиции лекарственных средств, содержащие их |
| CN102947298B (zh) * | 2010-06-22 | 2016-03-02 | 奇斯药制品公司 | 生物碱氨基酯衍生物及其药物组合物 |
| TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
| TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
| KR20140105746A (ko) | 2011-12-30 | 2014-09-02 | 키에시 파르마슈티시 엣스. 피. 에이. | 항무스카린제로서 1-아자헤테로시클릴아세트산의 퀴누클리딘 에스터, 이들의 제조 방법 및 이들의 의약 조성물 |
| CN104470503A (zh) | 2012-04-13 | 2015-03-25 | 葛兰素史克知识产权开发有限公司 | 聚集粒子 |
| WO2014007768A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
| KR20150075115A (ko) * | 2012-11-30 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제의 억제제 |
| SG11201600110RA (en) | 2013-07-11 | 2016-02-26 | Chiesi Farma Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| CN107569474A (zh) * | 2016-07-04 | 2018-01-12 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的药物组合物所用的载体的制备方法 |
| US11774363B2 (en) * | 2018-08-07 | 2023-10-03 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| IT201800007928A1 (it) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio |
| IL300652A (en) | 2020-08-14 | 2023-04-01 | Norton Waterford Ltd | Inhalable formulation of fluticasone propionate and albuterol sulfate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200102567T2 (tr) | 1999-03-05 | 2002-01-21 | Chiesi Farmaceutici S.P.A. | İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| DK1913939T3 (en) | 2000-06-27 | 2017-09-18 | Vectura Ltd | Formulations for use in inhalers |
| RU2296762C2 (ru) | 2000-12-22 | 2007-04-10 | Альмиралль Продесфарма Аг | Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе |
| GEP20063958B (en) | 2001-12-20 | 2006-11-10 | Chiesi Farma Spa | 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| ATE503517T2 (de) | 2002-07-31 | 2011-04-15 | Chiesi Farma Spa | Pulverinhalator |
| AU2003269989B8 (en) * | 2002-08-21 | 2009-11-12 | Norton Healthcare Ltd. | Inhalation composition |
| AR050902A1 (es) * | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| EP1882691A1 (en) | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| GB0811099D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination 376 |
-
2011
- 2011-05-30 CN CN201180030601.1A patent/CN102946868B/zh not_active Expired - Fee Related
- 2011-05-30 MA MA35474A patent/MA34326B1/fr unknown
- 2011-05-30 CA CA2803418A patent/CA2803418A1/en not_active Abandoned
- 2011-05-30 BR BR112012032330A patent/BR112012032330A2/pt not_active IP Right Cessation
- 2011-05-30 NZ NZ604983A patent/NZ604983A/en not_active IP Right Cessation
- 2011-05-30 MX MX2012014541A patent/MX2012014541A/es not_active Application Discontinuation
- 2011-05-30 EA EA201291306A patent/EA201291306A1/ru unknown
- 2011-05-30 PE PE2012002468A patent/PE20130282A1/es not_active Application Discontinuation
- 2011-05-30 EP EP11724158.8A patent/EP2585047A1/en not_active Withdrawn
- 2011-05-30 KR KR1020127033556A patent/KR20130111967A/ko not_active Application Discontinuation
- 2011-05-30 UA UAA201214589A patent/UA107499C2/uk unknown
- 2011-05-30 AU AU2011269238A patent/AU2011269238A1/en not_active Abandoned
- 2011-05-30 WO PCT/EP2011/058804 patent/WO2011160920A1/en active Application Filing
- 2011-05-30 SG SG2012094264A patent/SG186427A1/en unknown
- 2011-05-30 JP JP2013515798A patent/JP2013529606A/ja not_active Withdrawn
- 2011-06-21 AR ARP110102149A patent/AR081967A1/es unknown
- 2011-06-21 TW TW100121556A patent/TW201204412A/zh unknown
- 2011-06-22 US US13/165,955 patent/US20110308519A1/en not_active Abandoned
-
2012
- 2012-11-30 TN TNP2012000566A patent/TN2012000566A1/en unknown
- 2012-12-06 CL CL2012003450A patent/CL2012003450A1/es unknown
- 2012-12-20 CO CO12230869A patent/CO6640319A2/es active IP Right Grant
- 2012-12-20 ZA ZA2012/09682A patent/ZA201209682B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110308519A1 (en) | 2011-12-22 |
| TN2012000566A1 (en) | 2014-04-01 |
| SG186427A1 (en) | 2013-01-30 |
| UA107499C2 (uk) | 2015-01-12 |
| MA34326B1 (fr) | 2013-06-01 |
| AR081967A1 (es) | 2012-10-31 |
| NZ604983A (en) | 2014-07-25 |
| CA2803418A1 (en) | 2011-12-29 |
| CN102946868A (zh) | 2013-02-27 |
| MX2012014541A (es) | 2013-01-29 |
| WO2011160920A1 (en) | 2011-12-29 |
| KR20130111967A (ko) | 2013-10-11 |
| JP2013529606A (ja) | 2013-07-22 |
| CL2012003450A1 (es) | 2013-03-15 |
| CN102946868B (zh) | 2014-10-29 |
| BR112012032330A2 (pt) | 2016-11-08 |
| ZA201209682B (en) | 2014-03-26 |
| AU2011269238A1 (en) | 2013-01-10 |
| EP2585047A1 (en) | 2013-05-01 |
| EA201291306A1 (ru) | 2013-05-30 |
| TW201204412A (en) | 2012-02-01 |
| PE20130282A1 (es) | 2013-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6640319A2 (es) | Formulación en polvo seca que comprende una droga antimuscarínica | |
| WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
| CO6690744A2 (es) | Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| EA201590030A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| PE20141703A1 (es) | Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion | |
| NI201100066A (es) | Partículas inhalables que comprenden tiotropio. | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| MX348677B (es) | Peptidos ciclicos con actividad antineoplasica y antiangiogenica. | |
| WO2014007771A3 (en) | Inhalation compositions comprising muscarinic receptor antagonist | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| EA201590036A1 (ru) | Композиции для ингалятора сухого порошка, содержащие антагонисты мускариновых рецепторов длительного действия | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| CO2017004512A2 (es) | Composición farmacéutica que contiene budesonida y formoterol | |
| TR201000730A2 (tr) | Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| TR201000731A2 (tr) | Tiotropyum ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TR201000619A2 (tr) | Tiotropium ve mometazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TR201000624A2 (tr) | Tiotropium ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon. | |
| TR201000621A2 (tr) | Tiotropium ve budesonid içeren kuru toz formundaki farmasötik kompozisyon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |